The Effect of PPI on Endoscopic Treatment of WON: a Multicenter Randomized Controlled Trial.

Inclusion Criteria: 1. Patients aged 18 years or older and not exceeding 80 years of age. 2. Patients with a confirmed diagnosis of WON. 3. Patients requiring endoscopic ultrasound-guided transluminal drainage/debridement therapy. 4. Patients who have signed informed consent forms. Exclusion Criteria: 1. Patients diagnosed with chronic pancreatitis who have not experienced an acute pancreatitis attack within the past three months. 2. Patients with severe coagulation disorders (International Normalized Ratio \[INR\] \> 1.5). 3. Patients with significant thrombocytopenia (platelet count \< 50 × 10\^9/L). 4. Pregnant women. 5. Patients undergoing endoscopic drainage solely through the duodenum. 6. Patients with a history of gastrectomy, gastric bypass surgery, or prior surgery for pancreatic-related diseases. 7. Patients currently taking medications that may affect gastric acid secretion or metabolism, such as strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., clarithromycin, itraconazole) or inducers (e.g., rifampin, carbamazepine). 8. Patients requiring long-term use of acid-suppressing medications such as PPIs and P-CABs due to other medical conditions. 9. Patients with a history of acid-suppressive medication use (e.g., PPI) and a washout period of less than 14 days. 10. Patients with documented contraindications to PPIs or a relevant history of hypersensitivity.